Scientific Articles

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, Irene L M Reijers, Marta Lopez-Yurda, Alexander M Menzies, Annegien Broeks, Sten Cornelissen, Alejandro Torres Acosta, Anja van der Wal, Robyn P M Saw, Judith M Versluis, Winan J van Houdt, Michel W Wouters, Jurriaan Romano, Eliza A Rozeman, Lindsay G Grijpink-Ongering, Ellen Kapiteijn, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Hanna Eriksson, Geke A P Hospers, Jos A van der Hage, Dirk J Grünhagen, Arjen J Witkamp, Judith M Lijnsvelt, Willem M C Klop, Charlotte L Zuur, Annemarie Bruining, Abrahim Al-Mamgani, Thomas E Pennington, Kerwin F Shannon, Sydney Ch’ng, Andrew J Colebatch, Maria Gonzalez, Andrew J Spillane, John B A G Haanen, Robert V Rawson, Richard A Scolyer, Bart A van de Wiel, Alexander C J van Akkooi, Georgina V Long, Christian U Blank

Nature Medicine, 2026 Mar.

Link all’abstract

© 2026. The Author(s), under exclusive licence to Springer Nature America, Inc.
Privacy Overview
AIOM

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.